U.S. Dependence on China for Biopharmaceuticals Poses National Security Risk

According to a Council on Foreign Relations report, China is actively working to displace U.S. leadership in the biopharmaceutical value chain, raising concerns about national security and drug supply stability. This dependence affects the availability and development of medications across multiple therapeutic areas. The report highlights vulnerabilities in America's pharmaceutical manufacturing and innovation infrastructure. For patients, this geopolitical tension could impact drug accessibility, pricing, and the speed of bringing new treatments to market. Experts warn that reducing this dependency is critical for ensuring long-term healthcare security.